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IPSC BASED GENE CORRECTION AND DISEASE MODELING OF A NEW
CLASS OF LGMD DUE TO POGLUT1 MUTATION
Jose Ortiz-Vitali, B.S.
Advisory Professor: Radbod Darabi, PhD

Recently, a novel class of muscular dystrophy has been discovered in a family due to
autosomal recessive missense mutation in POGLUT1. Mutation of this enzyme leads to
decreased O-glucosyltransferase activity and impaired Notch signaling, the pathways
important for skeletal muscle stem cell (satellite cells) quiescence and activation. We
hypothesize that reduced POGLUT1 activity and impaired Notch signaling is causative of
this limb girdle muscular dystrophy through dysfunction of muscle stem cells and
myogenic progenitors.
To test this, we have used iPSCs for disease modeling and rescue experiments. Using a
CRISPR based gene targeting method, we aimed to correct the point mutation and
restore POGLUT1 function, thus restoring Notch signaling activity. Following correction,
iPSC-derived gene corrected myogenic cells were differentiated and compared to healthy
control and patient cell line (isogenic control). Compared to patient cells, gene-corrected
cells demonstrated superior ability to proliferate and improved myogenic potential as
compared to patient uncorrected cells. In addition, Notch signaling pathway activity was
improved in the corrected cells as a result of the POGULT1 gene correction. These results
support our hypothesis that POGULT1 modulates Notch signaling in myogenic cells and
its involvement may be responsible for the development of this type of LGMD.
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CHAPTER 1: INTRODUCTION
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1.1 Skeletal Muscle
Skeletal muscle makes up about a third or more of the human body’s total mass,
and its generation and regulation is a highly controlled step -wise process from
embyrogenesis to post-natal myogenesis and onwards into adulthood. From the
three germ layers that are formed in the embryo (ectoderm, endoderm, and
mesoderm) the mesoderm and subsequently the paraxial (also known as pre-somitic
or somitic) mesoderm gives rise to the sublayer that forms the skeletal muscle.
Following specification of the sublayers of the mesoderm in early embryogenesis, a
collection of signals from the dorsal ectoderm, neural tube, and notochord drive
somitogenesis and the generation of myogenic precursors (Zhao & Hoffman, 2004).
Somitic specification gives rise to the dermomyotome generating precursor cells
expressing the transcription factors PAX3 and PAX7, which regulate early skeletal
muscle formation, and post-natal growth and regeneration respectively (Relaix, et
al., 2006). Committed myogenic progenitors expressing MYF5 enter the cell cycle
and proliferate where they give rise to further committed MYOD+ cells that exit the
cell cycle eventually forming myoblasts that fuse and form MYOG +/MHC + myotubes
(Cusella-De Angelis, et al., 1992).

1.2 Satellite Cells: The Stem Cells of the Muscle
Within the highly organized skeletal muscle system there lies a system of
maintenance and regeneration by stem cells to repair damaged fibers while also
replenishing the pool of progenitors that give rise to the mature muscle. These cells
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are known as satellite cells; quiescent stem cells lying just beneath the basal lamina
of the myofiber which, upon injury, are activated and enter the cell cycle where it
asymmetrically, and symmetrically (Le Grand, Jones, Seale, Scimè, & Rudnicki,
2009)divides to restore their own pool of satellite cells or give rise to Pax7 + myogenic
progenitors that repair the damaged muscle (MAURO, 1961), (Schultz, E.,
Gibson,M.C., Champion, 1978), (Zammit, et al., 2004). Expression of Pax7 is
necessary for of myogenic specification and quiescence of satellite cells (Seale, et
al., 2000). While both PAX3 and PAX7 define myogenic progenitors, MYF5, MYOD,
MYOG, AND Desmin play an epistatic relationship to further drive terminal
differentiation of myoblasts (Rudnicki et al. 1993), (Kassar-Duchossoy, 2004).

1.2.1 Satellite Cells in Maintenance and Recovery
The process by which the myofiber is damaged and undergoes necrosis, followed
by activation, proliferation and differentiation of satellite cells ultimately ending in
new myofiber formation is known as muscle regeneration. Studies have shown that
targeted ablation of the satellite cell pool leads to lack of muscle regeneration
(Lepper, Partridge, & Fan, 2011), (Sambasivan, et al., 2011) further corroborating
the idea that this pool of satellite cells is critical for regeneration in adulthood
regardless of physiological or pathological injury. In the events following muscle
injury, satellite cells undergo a process of activation of the skeletal m uscle program,
and an upregulation of myogenic genes desmin, MyoD, myf5, and myogenin are
observed, though proliferation of satellite cells is not seen until after 24 hours
(Rantanen,Hurme, T., Lukka, R., Heino, J., Kalimo, 1995), (Cornelison & Wold,
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1997). Fundamental work in discovering the regenerative capacity of satellite cells
has shown that transplantation of single muscle fibers into radiation-ablated muscle
can generate numerous new myofibers containing thousands of nuclei. These
satellite cells are seen to proliferate and regenerate as well as self -renew (Collins,
et al., 2005).

1.2.2 Signaling Pathways Governing Satellite Cell Renewal and Commitment
To drive regeneration, the satellite cells asymmetric and symmetric division is
dependent on two key pathways: Notch and Wnt signaling. Symmetric distribution is
driven through activation of planar cell polarity through Wnt7a activation of Vang12
through Frizzled (Le Grand, Jones, Seale, Scimè, & Rudnicki, 2009). In asymmetric
division, the Notch pathway is involved. Notch signaling maintains quiescence in
satellite cells and its downregulation allows for committed progenitors to differentiate.
Notch signaling in muscle development and regeneration involves a complex
interplay of ligands and receptors the likes of which still requires full elucidation,
however many groups have begun to shed light on the combinatory functions of these
signaling molecules. Notch signaling molecules includes expression of four
receptors, Notch 1-4, and five canonical ligands DLL1, 3, and 4, and Jagged -1 and
-2. Notch 1 and 2 in satellite cells has been shown by conditional knockouts to
coordinate to regulate satellite cell function in the quiescent and activated state.
Interestingly, single knockout of Notch 1 and 2, and double knockout showed no
significant, slight reduction, and almost complete depletion of satellite cells in
quiescence respectively. However, in the activated state, single knockouts of both
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Notch 1 and 2 showed defect in regeneration and double knockout exhibite d severe
compromise of regeneration of the satellite cell pool. This shows Notch 1 and 2 must
work synergistically to maintain the stem cell pool in quiescence (Fujimaki et al.
2017). Transplantation experiments showed that satellite cells expressed high levels
of Notch3, whereas committed progenitors showed high levels of DLL1. Interestingly,
Notch3 deficient showed hyperplasia after repeated muscle injury and may act as a
negative feedback regulator of Notch signaling by repressing Notch 1 (Kitamoto et
al. 2010). In primary myoblasts, low levels of DLL1 existed in Myf5 - cells, but Myf5 +
cells exhibited high DLL1 levels. Upon inhibition of Notch signaling via DAPT (a γ secretase inhibitor essential for proper Notch signaling), loss of the Pax7 +/Myf5 satellite cell pool was seen showing Notch signaling plays a key role of regulating
self-renewal (Kuang, Kuroda, Le Grand, & Rudnicki, 2007).

1.3 Genetic Muscular Dystrophies
As stated previously, in normal adults’ muscle regenerates following injury or stress.
However, there exists a category of muscle disorders known as muscular
dystrophies. These are rare genetic diseases that affect the skeleta l muscle of the
body and are characterized by progressive muscle damage, and invasion of fatty and
fibrotic tissue within the muscle fibers, usually resulting in poor prognosis. There are
currently dozens of identified muscle disorders ranging from mutations in key
structural proteins of the muscle, signaling molecules, enzymes, and even errors in
post-translational modification.
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1.3.1 DMD and Other Common MDs
Of the 30 known types of muscular dystrophies, there are a handful that are
more prevalent than others. Duchenne Muscular Dystrophy, and its milder form
Becker Muscular Dystrophy, are the most common and well known. DMD affects 1
out of 3500 boys and is caused by a lack of dystrophin protein in the muscle achieved
through X-linked recessive mutation (reduced expression of dystrophin is the cause
of the milder form BMD) (Koenig, Monaco, & Kunkel, 1988). Dystrophin is expressed
at the sarcolemma and binds at the DAPC to help link the ECM and cytoskeleton
(Ervasti, Ohlendieck, Kahl, Gaver, & Campbell, 1990), (Yoshida & Ozawa, 1990).
Loss of dystrophin leads to progressive muscle wasting early in age, and eventual
death during or before teens by either cardiac or pulmonary failure. Another common
type of muscular dystrophy is Myotonic dystrophy, the most common type of adult
MD. DM is caused by an autosomal dominant mutation that leads to excessive CTG
repeats in the 3’ UTR (Mahadevan, et al., 1992). A unique type of MD known as
FSHD differs from the usual disruption of gene function in that a loss of a subset of
repeats in the D4Z4 macrosatellite repeat array of chromosome 4 does not disrupt
structure of any particular gene (TYLER & STEPHENS, 1950), (Tawil & Van Der
Maarel, 2006). Interestingly, a majority of FSHD cases experience de novo mutations
(Tawil & Van Der Maarel, 2006). Lastly, there is a heterogeneous group of MD that
has a wide range of types and causes known as limb girdle muscular dystrophy
(LGMD). This MD is characterized by progressive muscle wasting beginning in mid to-late teens and confining the patient to wheelchair later in adult life. Proximal
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muscles of the body such as those attached to the trunk of the body as well as back
and shoulders are most affected. Mutations in various components of the muscle
such as Lamin A/C, Caveolin-3, α-dystroglycan, and glucosyltransferases all lead to
various forms of LGMD which vary in severity (Galbiati et al. 2000), (Muchir, et al.,
2000), (Brown, et al., 2004), (Servián-Morilla, et al., 2016).

1.3.2 Satellite Cell Function in Muscular Dystrophies
With the regenerative function of satellite cells in muscle, one can come to the
conclusion that in DMD and other dystrophic patients, there must be a compensatory
mechanism and exhaustion of the satellite cell pool from repeated injury and stress
on muscles. In the mouse model for DMD (known as mdx) muscle degeneration in
early age activates satellite cells which results in increased proliferation (Boldrin,
Zammit, & Morgan, 2015) and with age, as well as disease progression, satellite cell
self-renewal is decreased. Interestingly, a group using a Notch-reporter mouse has
found that mdx satellite cells exhibit reduced activation of Notch signaling, which is
necessary to maintain satellite cell quiescence and self -renewal, with constitutive
Notch activation rescuing the self-renewal deficiencies (Kuang, Kuroda, Le Grand, &
Rudnicki, 2007). This further implies that Notch signaling is essential for maintaining
the satellite cell pool.

1.4 Discovery of LGMD2Z
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Recently, collaborators in Spain have discovered a novel form of LGMD referred
to as LGMD2Z. This disease arose in a consanguineous family where four out of five
of the siblings in the family harbor a homozygous recessive missense mutation in a
glucosyltransferase enzyme dubbed POGLUT1 (or Rumi in D. melanogaster) due to
a c.699 T>G transversion, which led to a change in codon sequence from aspartic
acid to glutamic acid at residue 233 (p.D233E). This enzyme is involved in Notch
signaling post-translational modification and function. Patient muscles show reduced
Notch signaling activity, decreased satellite cell pools, and hypo -glycosylation αdystroglycan (Servián-Morilla, et al., 2016). Patient-derived myoblasts also showed
decreased proliferation, aberrant differentiation, and overall decreased pool of Pax7 +
cells. Due to the decreased satellite cell pool and disrupted differentiation, it is
believed that pathology is driven through Notch-dependent loss of satellite cells
(Servián-Morilla, et al., 2016).

Figure 1 Family Pedigree Showing POGLUT1 Missense Mutation: Three
out of five family members harbor the homozygous recessive missense
mutation in POGLUT1. Characteristic of LGMD is winging of scapula seen in
patients 1, 2, 4, and 5.
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1.4.1 Notch Signaling and Satellite Cell Depletion in LGMD2Z
In the Notch signaling pathway, neighboring cells communicate via exchange
through the Notch intracellular and extracellular transmembrane which facilitates
cell-to-cell contact. Interactions with ligands leads to a series of proteolytic cleavage
carried out by ADAM for the NECD and γ-secretase for release of the NICD from the
cytosolic side of the membrane. Following cleavage, the NICD translocates to the
nucleus where it complexes with binding proteins and transcriptional coactivators to
activate expression of Notch target genes (such as the HES family of proteins (Kopan
& Ilagan, 2009). Within the NECD lies a series of EGF repeats that contain a
consensus sequence CXSX(P/A)C (Rana, et al., 2011). It is within these EGF repeats
that post-translational modification of the NECD occurs. The NECD is modified with
O-fucose and O-glucose glycans depending on the context in a tissue-specific
manner and, if altered, affects Notch signaling. POGLUT1 plays a role in Notch
signaling by adding O-glucose repeats to serine residues within the EGF repeats of
the NECD. This post-translational modification is responsible for the NICD cleavage
event by γ-secretase and improper cleavage leads to reduced Notch signaling
activity (Acar, et al., 2008). POGLUT1 knockdown in mouse C2C12 cells has shown
a decrease in O-glucosyltransferase activity and impaired Notch signaling
(Fernandez-Valdivia, et al., 2011). As a result of decreased Notch signaling, proper
activation of Pax7 does not occur, leading to progressive wasting of the satellite cell
pool. Treating C2C12 cells with DAPT also shows decreased levels of Pax7 mRNA,
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which is also seen in the muscles of patients. Interestingly, this wasting of the
satellite cell pool does not occur immediately, but progressively, and patients have
lived into early adulthood before disease progression becomes severe, ultimately
confining them to wheelchair and severely limiting the use of the proximal muscles
of the body (Servián-Morilla, et al., 2016). This is due to the otherwise normal
development of the satellite cell pool, and a compensatory mechanism of regeneration of
the limited pool before depletion.

1.5 Objectives and Hypothesis
We hypothesize that the POGLUT1 D233E missense mutation is causative of
LGMD2Z affecting the Notch pathway to the extent of causing reduced Notch
signaling, expansion, and self-renewal of satellite cells/myogenic progenitor cells
and accelerated differentiation to myofibers.

1.5.1 Specific Aim I: CRISPR/Cas9n Based Gene Correction of POGLUT1
Mutation in Patient-Derived iPSCs: A pair of site specific Cas9n gRNA
constructs targeting the mutation region of POGLUT1 were delivered via
electroporation along with a targeting construct containing two homology arms
for POGLUT1 flanking a T2A-RFP-PURO selection cassette to generate DSB
and facilitate HDR. This targeting construct contained loxP sites for removal
of the selection cassette following selection and validation. Correction was
verified via PCR analysis and DNA sequencing.
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1.5.2 Specific Aim II: In Vitro Disease Modeling of Gene Corrected and PatientDerived iPSCs: Following validation of correction, control (CTL), patient (PT)
and patient-corrected (PTC) cell lines underwent a directed differentiation
protocol developed by our lab to validate reversal of pathology. This protocol
recapitulates skeletal muscle myogenesis by driving cells towards PSM
lineage followed by activation of dermomyotomal muscle progenitor cells.
Validation of reversal of pathology will assist in further elucidating the role of
POGLUT1 in Notch signaling.
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CHAPTER 2: MATERIALS AND METHODS
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2.1 Generation of iPSC line from Patient with LGMD2Z
Generation of LGMD2Z cell line is previously published data from the laboratory and
referenced in the bibliography (Wu, et al., 2017).

2.2 Generation of Targeting Construct
Dr. Jianbo Wu of our laboratory previously generated the gRNA targeting sites for
generation of DSB. In silico multiple possible target sites were generated and tested by
SURVEYOR assay to determine %indel formation to estimate cutting efficiency. For
construction of the targeting vector, the 3’ end of the POGLUT1 homology arm was cut
out of the pStartK backbone construct (Figure 1) which contained a 5’ and 3’ homology
arm using restriction endonucleases NEB EagI-HF (Catalog #R3505S) and EcoRI-HF
(Catalog #3101S) with NEB CutSmart® buffer (Catalog #B7204S) digested at 37°C for 3
hours. The 3’ fragment of the POGLUT1 homology arm was then PCR amplified with
conditions: initial denaturation at 95°C for 3 minutes; followed by 40 cycles of 95°C for 30
seconds, 62°C for 30 seconds, and 72°C for 1 minute followed by a final extension at
72°C for 10 minutes. PCR products were verified using 1% TAE agarose gel
electrophoresis, ran for 30 minutes at 120V, and then purified using the Promega
Wizard® SV Gel and PCR Clean-Up kit (Catalog #A9280). Once removed, the pStartK
backbone that that had been cut was also purified using the Promega Wizard® SV Gel
and PCR Clean-Up kit. Similarly, the selection cassette containing EF1 driven RFP T2A
and Puromycin resistance was cut out of a pcDNA3.1 backbone (Figure 1) using NEB
13

Not1-HF (Catalog #3189S) and EcoR1-HF (Catalog #3101S) with NEB CutSmart® buffer
(Catalog #B7204S) digested at 37°C for 3 hours.

a)

b)

SalI (120)

Amp(R)

CMV promoter
EcoRI (953)

POGLUT1-5-arm
KanR

EcoRV (965)

pUC origin

pK-POGluT1-arms
5193 bp

pcDNA3.1-RFP-Puro
8336 bp

EcoRI (1242)

EF1-RFP-Puro

Neo(R)
p15A ori

POGluT1-3-arm

EcoRV (3041)

SV40 early promoter
Not I (3888)

EagI (2618)

Figure 2 Tageting Construct Vectors: a) pStartK backbone containing POGLUT1 5’
and 3’ homology arms with unique EagI and EcoR1 sites to remove 3’ arm. b) pcDNA3.1
backbone containing EF1-RFP-T2A-Puromycin selection cassette and specific cutting
sites Not1 and EcoR1 for removal of the selection cassette.
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The puromycin selection cassette purified from the pcDNA3.1 backbone and
pStartK backbone containing only the 5’ POGLUT1 homology arm were then ligated using
the NEB NEBuilder® HiFi DNA Assembly Kit (Catalog #E5520S) as per the kit’s
instructions. To verify correct ligation of the pStartK backbone with 5’ homology arm and
puromycin resistance cassette, the construct was digested with NEB RsrII (Catalog
#0501S) and CutSmart® buffer (Catalog #B7204S) digested at 37°C for 1 hour. Digested
products were visualized on a 1% TAE agarose gel and ran for 30 minutes at 120V.
Expected band sizes include 4.0kb, 1.5kb, and 1.1kb (Figure in results). Following
verification of correct ligation, the construct was cut with Not1-HF (Catalog #3189S) to
open for ligation. The purified 3’ homology arm was then ligated back into the construct
using NEB Gibson Assembly® kit (Catalog #E5510S) as per kit instructions. To verify
correct insertion of 3’ POGLUT1 homology arm, the construct was digested with NEB
HindIII (Catalog #0104S) for 1 hour at 37°C. Digested product was then visualized using
a 1% agarose gel ran for 30 minutes at 37°C. Expected bands were: 4.5kb, 2.3kb, and
1.6kb (Figure in results). Lastly, to generate the final construct to be used for targeting, a
Gateway® cloning reaction using Thermo Fisher Gateway® LR Clonase® II (Catalog
#1179120) was performed to transfer the construct from a pStartK backbone to pWSTK6. Following Gateway® reaction, the reaction was transformed into One Shot ®
OmniMAX™ 2 T1R chemically competent E. coli. Cells were incubated on ice for 30
minutes, heat shocked for 30 seconds at 42°C, and placed on ice for 2 minutes. Cells
were recovered with pre-warmed SOC broth and expanded for 1 hour at 37°C in shaking
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incubator at 200rpm. Bacteria was then seeded onto ampicillin plates and grown
overnight at 37°C. Final Construct is as seen in Figure 3.

attB2

Mini-TK promoter

POGluT1-3-arm

HSV TK 5'-UTR
HSV TK

loxp
core insul

HSV TK poly(A) signal

EF1 promoter

pWS-POGluT1-arms-Puro-RFP

Ruby

10154 bp

pBRforEco
AmpR promoter
Amp-R

T2A

AmpR

Puro
SV4O polyA
core insul
loxp

T7
Asc I (4426)

mutation

Asc I (4438)

Exon 7
POGLUT1-5-arm

Figure 3 Map of Final Targeting Construct:
Map features include 5’ and 3’ POGLUT1 homology arms, puromycin selection cassette
with EF1 promoter and T2A linking RFP Ruby and Puromycin resistance all flanked by
loxP sites for removal after selection and HSV TK resistance for negative selection.
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2.3 Electroporation of Cas9n Pair and pWS-POGLUT1-TK6-Puro construct
To prepare PT II.5 cells for electroporation, cells were grown in mTeSR™1
medium (Stem Cell Technologies, Catalog #85850) until 75% confluent and switched to
MEF conditioned hES cell medium for two days supplemented with hr-FGF prior to
electroporation: DMEM/F12 w/ GlutaMAX™ (Gibco, Catalog#10565018), 20% KSR™
(Gibco, Catalog #10828028), 1% MEM NEAA (Gibco, Catalog #11140050), 0.18% BME
(Gibco, Catalog #21985023), 1% PS (Gibco, Catalog #15140122), 20ng/ml hr-FGF
(Pepro Tech Inc, Catalog #100-18B). Once cells reached 60-80% confluency, cells were
detached using ACCUTASE™ cell detachment solution (Stem Cell Technologies,
Catalog #07920), pelleted at 200xg for 5 min, washed with PBS, and re-suspended in
100ul Lonza P3 Primary Cell 4D-NucleofectorTM solution containing 4μg of each construct
(pWS targeting construct and two Cas9n sgRNA constructs) for nucleofection in the
Lonza 4D-NucleofectorTM X unit (Lonza, Catalog #4VXP-3032). Cells were electroporated
according to protocol CA139. Cells were recovered in complete hES medium and seeded
onto gelatin coated dishes with B6 Puromycin resistant MEF cells (Gibco, Catalog
#A34965) supplemented with ROCK inhibitor Y27632 (Millipore Sigma, Catalog #Y0503).
Cells were allowed to recover until large noticeable colonies were formed from single cells
and then treated with Puromycin to select for positive clones.

2.4 Expansion and validation of single-cell derived iPSC Clones
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Following selection, puromycin treatment continued for ten days until colonies
grew visibly once again to a large round shape and were picked. Picking colonies involved
physical removal by creating grid pattern on the clone with 18g needle and removal with
pipette. 30 colonies were seeded onto Corning Matrigel (Catalog #356234) coated plates
with mTeSR™1 medium supplemented with Y27632. Cells were spun at 500 x g for 30
minutes at RT to promote attachment and increase survival of single-cell derived clones.
Once picked colonies recovered, puromycin treatment was started again and maintained
until cells were verified and frozen for stock. gDNA was extracted from picked clones
using Lucigen QuickExtract™ DNA extraction Solution as suggested by protocol. gDNA
extracted was used for PCR screen of primers (Table 1) amplifying the 5’ and 3’ regions
of the POGLUT1 gDNA and spanning the selection insert. Primers (Table 1) to detect the
wild type POGLUT1 without presence of the selection cassette was used as well for
control. Clones picked that were screened positive were sent for DNA sequencing at
LSLabs in the Texas Medical Center using reverse primer (Table 1) of 5’ POGLUT1
homology arm which contains the region of the correction. Sequencing results analyzed
using Chromas software. Following expansion of clones, puromycin selection cassette
was removed by electroporation of 4μg Cre recombinase plasmid pCAG-Cre-IRES2-GFP
(Addgene, Catalog #26646). Lonza 4D nucleofector P3 Kit as described before. Clones
were seeded and expanded on multiple Corning matrigel (Catalog #356234) coated 96
well plates and allowed to recover with mTeSR™ Plus (Stem Cell Technologies, Catalog
#05825) supplemented with CloneR™(Stem Cell Technologies, Catalog #05889) to
increase survival of single-cell derived colonies. Once single-cell derived clones were
identified, clones were expanded to larger wells while screening with primers specific to
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loxP sites and POGLUT1 sequence (Table 1). Following expansion of PTC clones verified
for correct removal of puromycin selection cassette, positive clone was stained for iPSC
markers using Stemlight™ iPSC Reprogramming Antibody Kit (Stemlight™, Catalog
#9092S) as per kit instructions.

Oligo Name

Sequence 5' to 3'

POGLUT1-783Mut-F

TGACCTGAACAACATACCCTTCA

POGLUT1-783Mut-R

GCTAATGCTGGTTCATGGAACTT

POGLUT-783Mut-seq-F

GTCCTAGTCCTGCTCACCTT

POGLUT1-5’ arm-F

tgcttgtcgacGAAAAGACCATGAAGGGAGC

POGLUT1-3’ arm-R

tcgagtgcggccgcacAACATTTGGAACTGTTAGTATTCTCTC

POGLUT1-5’ arm-R

gtctaggaattcttgaatataacttcgtataatgtatgctatacgaagttatGTTCATGGAACTTTCTTTACATTCACC

POGLUT1-3’ arm-F

tatcacgaattcaaacatataacttcgtatagcatacattatacgaagttatCAGCATTAGCATATATGTAAATTCTCC

POGLUT1-SUR-F1

CTCACCTTTCAGGGATTGGGAA

POGLUT1-SUR-R1

AGAGTGGACTGTAAACCAACGG

Table 1 Primer Sequences Used for Generation of Targeting Construct: Primers
were generated using VectorNTI analysis for optimal primer sites and amplification of
target sequence. Same primer sets, such as 5’ and 3’ primer sets as well as SUR primers
were used for verification of correct insertion and verification of loxP removal.
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2.5 In Vitro Differentiation of CTL, PT, and PTC iPSCs to Skeletal Muscle
a)

b)

Figure 4 Myogenic differentiation of CTL, PT, and PTC iPSCs: a) Involves 5 day
induction of mesoderm with a Wnt activator and TGF- β inhibitor followed by 10 days of
selection for dermomyotome specification with TGF- β inhibitor and inhibition of BMP.
b) Plans for expansion and sample harvesting after Day 15. Terminal differentiation
involves staining for MHC and Myogenin for each cell line.
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Previously published protocol as seen detailed in Figure 4 (Wu, et al., 2018)
by our laboratory involves skeletal muscle differentiation in three stages.
Reprogrammed iPSCs CTL, PT, and PTC were harvested using ACCUTASE™ cell
detachment solution (Stem Cell Technologies, Catalog #07920), and seeded onto
Corning Matrigel (Catalog #356234) coated plates at 30,000 cells/cm2 in MDM-I and
maintained for 5 days. MDM-I contained IMDM (Gibco, Catalog #12440053), 5% HS
(Gibco, Catalog #26050088), 3 μM CHIR99021 (Selleck Chemical LLC, Catalog #S1263),
3 μM SB431542 (Selleck Chemical LLC, Catalog #S1067), 10 ng/ml hr-EGF (PeproTech
Inc, Catalog #100-47), 10 μg/ml insulin (Millipore Sigma, Catalog #I9278), 0.4 mg/ml
dexamethasone (Millipore Sigma, Catalog #D4902) and 200 μM L-ascorbic acid (Millipore
Sigma, Catalog #A4403). Following 5 days of MDM-I, cells were harvested using
ACCUTASE™ cell detachment solution (Stem Cell Technologies, Catalog #07920), and
seeded onto Corning Matrigel (Catalog #356234) coated plates at 30,000 cells/cm 2 in
MDM-II. MDM-II contained IMDM (Gibco, Catalog #12440053), 5% HS (Gibco, Catalog
#26050088), 3 μM SB431542 (Selleck Chemical LLC, Catalog #S1067), 0.5 μM
LDN193189 (Stemgent, Catalog #04-0074-10), 10 ng/ml hr-EGF (PeproTech Inc,
Catalog #100-47), 10ng/ml hr-FGF (Pepro Tech Inc, Catalog #100-18B), 10ng/ml hr-IGF
(Pepro Tech Inc, Catalog #350-10), 10ng/ml hr-HGF (Pepro Tech Inc, Catalog #100139H), 10 μg/ml insulin (Millipore Sigma, Catalog #I9278), and 200 μM L-ascorbic acid
(Millipore Sigma, Catalog #A4403). Cells were cultured until Day 15 on differentiation,
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and then sorted using flow cytometry core with BD FacsAria II machine for CD10 + CD24population to enrich for myogenic progenitors (Wu, et al., 2018). Plan for harvesting of
samples for RNA and western blot as well as differentiation and immunostaining shown
in Figure 4 bottom image. Sorted cells were then plated on Corning Matrigel (Catalog
#356234) coated plates at 30,000 cells/cm2 in MDM-II to expand for terminal
differentiation. Once cells reached full confluency media was switched to MDM-III. MDMIII contained: DMEM/F12 with GlutaMAX™ (Gibco, Catalog#10565018), 1% CTS N-2
Supplement (Gibco, Catalog #A1370701), 100 μM SB431542 (Selleck Chemical LLC,
Catalog #S1067) (Hicks, et al., 2018). Cells were allowed to differentiate for 3 days then
fixed for immunostaining.

2.6 Gene Expression Analysis of Differentiation
During time-course of differentiation, samples were seeded onto 6-well plates,
2 wells of which were used for RNA samples. Cells were directly lysed with TRIzol
reagent (Invitrogen, Catalog #15596026) and stored at -80°C. Takara PrimeScript™
1st strand cDNA Synthesis Kit was used to generate cDNA as per kit instructions
(Clontech, Catalog #6110B). cDNA quality was verified by 3% agarose gel
electrophoresis for GAPDH (Table 1). qPCR analysis was done on three biological
replicates of differentiation samples, with two experimental replicates per sample.
TaqMan™ universal PCR master mix (Applied Biosystems, Catalog #4304437) was used
to carry out qPCR with TaqMan™ Gene Expression Assay Probes for Myogenic and
Notch related genes as well as housekeeping as shown in Table 2 below. Ct values
analyzed using SDS 2.4 ABI software and Microsoft Excel.
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Probe

ID#

GAPDH
POGLUT1
NOTCH1
NOTCH3
DLL1
HEY1
HES1
PAX3
PAX7
MYOD1
MYF5
MYH3

Hs02786624_g1
Hs00220308_m1
Hs01062014_m1
Hs00166432_m1
Hs00194509_m1
Hs00232618_m1
Hs00172878_m1
Hs00240950_m1
Hs00242962_m1
Hs00159528_m1
Hs00929416_g1
Hs01074230_m1

Amplicon Length
(bp)
157
90
80
87
74
66
78
145
73
67
114
65

Table 2 Probes from Applied Biosystems Gene Expression Assays used in qPCR
analysis of myogenic differentiation.
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2.7 Immunofluorescence and Quantification of MHC and MYOG
Cells were allowed to differentiate in MDM-III and fixed with 4% PFA (4% w/v
Paraformaldehyde (Acros Organics, Catalog #41678-5000) in dPBS/Modified solution
(HyClone, Catalog #SH30028.02)) for 15 minutes at RT and then washed with PBS 3x,
followed by 0.3% Triton X-100 (Promega, Catalog #H5142) for 30 minutes at RT. Next, a
3% BSA solution (3% w/v BSA (Fisher Bioreagents, Catalog #BP1600-100) in
dPBS/Modified solution (HyClone, Catalog #SH30028.02)) for 1 hour at RT followed by
overnight incubation with primary antibody diluted in 3% BSA solution (MHC Supernatant
adult MF20 DSHB antibody Catalog #MF20, AB_2147781 at 1:20 dilution; MYOG BD
monoclonal antibody Catalog #556358 at 1:200 dilution). Overnight antibody washed the
next day 3x with PBS for 5 minutes each then incubated 1 hour RT with secondary
antibody diluted 1:500 with PBS (MHC with Invitrogen Goat Anti-Mouse IgG Alexa Fluor®
555 Catalog #A28180; MYOG with Invitrogen Goat Anti-Mouse IgG Alexa Fluor® 488
Catalog #A11001). Cells washed with PBS and then incubated with DAPI solution
(Millipore Sigma, Catalog #508741) for 10 minutes at RT. Following DAPI staining, cells
washed 2x for 5 minutes each and then imaged for quantification of MHC +/DAPI+ cells
and MYOG+/DAPI+ cells. 6 images/well/cell line/marker. Images processed using ImageJ.

2.8 POGLUT1 Western Blot Analysis of Notch and Effectors
Protein samples were sent to the laboratory of Dr. Hamed Jafar-Nejad for
western blot analysis. As per the laboratories protocol: Total proteins were quantified
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using Pierce BCA Protein Assay (Cat #23228) and bovine serum albumin was used as
standard. Protein extracts (20 μg per well) were separated on a 12% SDS-PAGE miniPROTEAN TGX Precast gel (Bio-Rad Cat# 456-1046) and transferred onto PVDF
membranes (Bio-Rad Cat# 1620177). Membranes were blocked in 5% skim milk
powder in TBS-T at room temperature for 1 hour. Primary antibodies were diluted in
blocking buffer and incubated with the membrane overnight at 4 o. The antibodies used
in this study are Notch1-ICD, 1:1000 (Cell signaling Cat# 4147), NOTCH2-ICD, 0.5
µg/ml (DHSB Cat#C651.6DbHN), HES1, 1;1000 (Cell Signaling Cat# 11988), and
Tubulin, 1:2000 (Santa Cruz Biotechnology Catalog #sc-5274).

2.9 Statistical Analysis
All statistical data processed using Microsoft Excel functions including 2 tail T-test,
Mean, Standard Deviation, and Standard Error. All graphs and tables were also made in
Microsoft Excel.
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Chapter 3: Results
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3.1 Generation of Targeting Construct
When generating the targeting construct, the 3’ POGLUT1 homology arm was
removed from the pStartK construct to allow for ligation of the puromycin selection
cassette from pcDNA3.1 into the pStartK construct. Restriction digest with Eag1 and
EcoR1 removed the 3’ homology arm from the construct, and gel electrophoresis
confirmed presence of the 3’ arm (Figure 5). Following removal of the 3’ homology arm,
the cut pK-Poglut1-5’arm construct was purified and quality verified by Thermo
Scientific™ NanoDrop 2000 (A260/280 ratio: 1.96). Next, the removed puromycin
selection cassette was ligated into the pK-poglut1-5’arm construct using NEB
NEBuilder® HiFi DNA Assembly Kit and verified with restriction digest for RsrII (Figure 6).
Digest showed expected band sizes of 1.1 kb, 1.5 kb, and 4.0 kb. Clone 1 was chosen to
move forward with generation of the targeting construct. Following ligation of puromycin
selection cassette from pcDNA3.1 into the pK-poglut1-5’arm unfinished construct, the 3’
homology arm was ligated back into the construct using NEB NEBuilder® HiFi DNA
Assembly Kit and verified with restriction digest for HindIII (Figure 7). Expected band sizes
were observed and construct was purified for final Gateway® reaction into pWS-TK6
construct. Following Gateway® reaction, agarose gel electrophoresis verified the HindIII
digest gave expected band sizes of 1.1, 1.5, 1.8, and 5.7 kb as seen in Figure 8. Proper
digestion verified the targeting construct is ready to generate PTC cell line.
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Figure 5 PCR Amplification of 3’ POGLUT1 Homology Arm: PCR with 3’arm
specific primer (Table 1) shows correct amplicon length of 1.3 kb and saved for later
ligation back into the targeting construct prior to Gateway ® reaction (both lanes are
POGLUT1 3’ arm)
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Figure 6 RsrII Digest of Partial Construct Clones 1-6: Digest with RsrII showing
expected band sizes of 1.1, 1.5, and 4.0 kb. Clones 3, 5, and 6 are either negative or did
not digest properly.
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Figure 7 HindIII Digest of pK-Poglut1-Puro Construct: 5 clones were picked from
Gibson assembly digest and verified for correct ligation and product sizes following digest.
Expected band sizes are as follows: 1.6, 2.2, and 4.2 kb.
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Figure 8 RsrII Digest of Final pWS-Poglut1-TK6-Puro Construct: RsrII digest on 1%
agarose gel electrophoresis verifies expected band patterns of 1.1, 1.5, 1.8, and 5.7 kb.
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3.2 Electroporation of pWS-Poglut1-TK6-Puro into PT II.5 and Expansion of Clones
Clones were observed prior to electroporation to ensure healthy and typical iPSC
colonies are being used for electroporation (Figure 9). Following electroporation, cells
were allowed to recover for 72 hours before starting puromycin treatment for selection.
Figure 10 shows progression of cell recovery following electroporation to day 3, and then
from the beginning of puromycin treatment for 7-10 days depending on when colonies
were picked.
30 clones were picked and expanded, and 4 clones amplified positive for the
5’ and 3’ homology arm, two of which are shown in Figure 11 with expected band
size of 1.7 kb versus no amplification in uncorrected PT II.5. Clones were then
analyzed by DNA sequencing to verify correction of T>G mutation. Sequencing results
indicate successful homologous recombination and correction in Clone 9 out of the four
clones that showed positive for correct insertion. Figure 12 shows CTL, PT and PTC
sequencing. Healthy control shows wild type thymine at c.699, however in PT the
mutation changes to guanine, (T>G), changing the coding sequence from aspartic acid
to glutamic acid (D233E). Sequencing of Clone 9 PTC indicates proper correction of
mutation with reversal to guanine at c.699 (G>T). Prior to electroporation with pCAG-CreIRES2-GFP construct for removal of selection cassette, PTC Clone 9 was expanded to
ensure proper iPSC morphology (Figure 13).
PTC Clone 9 was then electroporated with pCAG-Cre-IRES2-GFP construct for
removal of puromycin selection cassette. Expansion of Cre recombinase treated clones
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yielded dozens of clones of which 24 were picked for screening. Figure 14 shows
expansion of clones in first four days of CloneR™ treatment.
Detection of successful removal of the selection cassette involved careful
generation of a primer pair that spanned the length of the POGLUT1 genomic DNA to
the single loxP site present after removal. If the primers did not amplify, this indicates
the presence of the puromycin selection cassette. Indeed, the selection cassette was
removed in 5 out of 7 clones screened and gave expected band sizes of 696 bp and
954 bp as shown in Figure 15.
Following verification and expansion for several passages of Cre-treated PTC
Clone 9, iPSC pluripotency markers were stained to verify maintenance of pluripotency
in the cell line. Indeed staining shown in Figure 16 shows consistent expression of
pluripotency markers C-MYC, NANOG, OCT4a, SOX2, and KLF4.

33

Figure 9 Morphology of PT II.5 iPSC: Morphology of PT II.5 prior to
electroporation. Colony morphologies show typical iPSC shape, undifferentiated
and healthy.
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+3 Day (Start Puromycin)

+1 Day

+5 Day

+10 Day

Figure 10 Recovery of Targeted PT II.5 from D0 - D10 Following Electroporation:
Cells were recovered for 72 hours and then treated with puromycin for selection for
7-10 days until clones were picked. Single cell derived colonies indi cated by red
arrows. (4x magnification).
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Figure 11 PCR of Uncorrected PT II.5 Versus clones 9 and 25: Expected band
sizes for both the 5’ and 3’ arm are 1.7 kb.
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CTL

PT

PTC

Figure 12 Sequencing results of CTL, PT, and PTC Clone 9: Sanger sequencing data
indicates healthy control contains thymine at highlighted c.699, whereas PT II.5 indicates
presence of T>G (thymine to glutamine) transversion missense mutation. This changes
the protein translation of the codon from aspartic acid to glutamic acid (D233E). Clone 9
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PTC sequencing confirms reversal of glutamic acid to aspartic acid at the indicated
position and change back to original codon.

Figure 13 Morphology of iPSC PTC Clone 9: Morphology of clone shows round typical
iPSC shape and lack of differentiated cells within culture (10x magnification).

38

Figure 14 CloneR™ expanded cells after Cre recombinase: Following 4 days of
CloneR™ expansion, PTC Clone 9 iPSCs revealed typical iPSC morphology and high
survival. Cells were picked within 7-10 days. (4x magnification)
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Figure 15 Gel electrophoresis of Cre Clones 1-7: Band sizes of PCR amplicons show
expected sizes of from the 5’ region (Top) and 3’ region (bottom).
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Figure 16 iPSC Pluripotency Marker Staining of Clone 9 PTC: Staining
indicates proper expression of pluripotency markers C-MYC, NANOG, OCT4a,
SOX2, and KLF4. (10x magnification)
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3.3 In Vitro Differentiation of CTL, PT, and PTC iPSCs to Skeletal Muscle
Using a recently published protocol by our laboratory (Figure 4), CTL, PT and PTC
cell lines were differentiated towards skeletal muscle lineage. During passage points and
intermediate time points, cells were harvested and counted to assess proliferation. Indeed
across the time points until Day 15, PTC cell line showed rescue of proliferation when
compared to PT (Figure 19). At day 15, samples were harvested and prepared for sorting
using CD10+ CD24- cell surface markers previously discovered by our laboratory to mark
a specific group of myogenic cells to enrich for myogenic differentiation potential (Wu et
al. 2018) (Figure 17). In the evaluation of CD10+ CD24- expression in myogenic progenitor
cells, PTC exhibited higher expression of CD10 (a marker expressed on myogenic
progenitors using this protocol) when compared to uncorrected PT cell line (P<0.05)
(Figure 18). Once cells reached the point of terminal differentiation and fully confluent
(Day 20), cells were switched to MDM-III and differentiated for three days and then fixed.
Analysis of MHC+ and MYOG+ myotubes showed statistically significant difference in
MHC+ and MYOG+ cells in PTC cells versus the uncorrected PT (P<0.001;P<0.05
respectively, Figures 20 and 21). Immunofluorescence image quantifications also
confirmed a significant increase in MHC+ and MYOG+ myofibers in PTC versus PT
(Figures 22 and 23).
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Figure 17 CD10+ Percentage of Expression in Sorted Cell Populations: In sorted
cells, CD10+ expression across all 3 sample sets (marker of myogenic cells using this
protocol) showed significantly higher myogenic population in corrected cells versus
uncorrected (P<0.05).

43

CD24

PTC

CD10

PT

CD10

CD10

CTL

CD24
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Figure 18 Gating of CD10+ CD24- Cell Populations in Set 3 of Differentiation: Gating
shows high percentage of myogenic cells in corrected (right) and control (left) versus
uncorrected (center) cells.
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Figure 19 Proliferation curve showing growth of CTL, PT, and PTC cells during
differentiation: Growth curves generated for time points Day 0, 5, 10,
** and 15 in each
cell line.
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Figure 20 Percentage of MYOG+ cells in myotubes: Quantification of MYOG+
cells compared to total number of DAPI+ cells in the field. Images quantified at 6
images/well. PTC compared to uncorrected PT shows statistically significant
higher number of MYOG+ cells (P<0.05).
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Figure 21 Percentage of MHC+ cells in myotubes Quantification of MHC+ cells
compared to total number of DAPI+ cells in the field. Images quantified at 6
images/well. PTC compared to uncorrected PT shows statistically significant
higher number of MHC+ cells (P<0.001).
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Figure 22 IFS imaging of CTL, PT, and PTC: IFS images show CTL (top row), PT
(middle row), and PTC (bottom row) stained with MYOG and DAPI. Images clearly show
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increased level of MYOG+ nuclei in fibers in the PTC cells versus PT after differentiation
of the cells (MYOG in green, DAPI in blue).

Merge
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CTL

PT

PTC
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DAPI

Figure 23 IFS imaging of CTL, PT, and PTC: IFS images show CTL (top row), PT
(middle row), and PTC (bottom row) stained with MHC and DAPI. Images clearly show
higher levels of percentage of MHC+ fibers, total amount of cells, as well as length and
quality of the fibers in PTC vs PT cells (MHC in red, DAPI in blue).

3.3.1 Gene Expression Analysis of Notch and Myogenic Genes
Gene expression results of Notch related genes and Poglut1 showed higher
expression in corrected cells in NOTCH1, HES1, HEY1, AND DLL1, while POGLUT1 and
NOTCH3 are more or less consistently equal across time points or uncorrected cells are
expressing higher than corrected, respectively. Myogenic genes showed higher levels of
mRNA expression in uncorrected in MYF5, MYOD1, and PAX3, whereas MHC3 and
PAX7 show higher levels of expression in corrected cells (Figures 24 and 25
respectively).
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Figure 24 qPCR Analysis of POGLUT1 and Notch Signaling Genes: qPCR analysis involved
major genes involved in the Notch pathway. Involved POGLUT1, NOTCH1, NOTCH3, ligand
DLL1 (T;P<0.005), and downstream effectors HEY1 and HES1 (T; P<0.005).
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Figure 25 qPCR Analysis of Myogenic Signaling Genes: qPCR analysis involved
major genes in the myogenic signaling pathway involving MYF5 (D15; P<0.001),
MYOD1 (T; P<0.05), MHC, PAX3 and PAX7 (D5; P<0.001, D15; P<0.001).
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3.3.2 Protein Analysis of Notch Intracellular Domains and Effector Hes1
Western Blot analysis shows N1ICD and N2ICD showed rescue in corrected cells
versus uncorrected. Likewise, there is a significant level of recovery in the presence of
downstream effector of Notch, Hes1 in corrected versus uncorrected cells. Tubulin
samples indicated consistent and similar levels of expression confirming the quality of the
protein samples (Figure 30).
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Figure 30 Western Blot of Notch Signaling Proteins: Western blot samples prepared
by Dr. Nima Niknejad from the lab of Dr. Hamed Jafar-Nejad. N1ICD, N2ICD, and
downstream effector Hes1 shown along with positive control Tubulin. Protein expression
seen in NICD seem to be increased in PTC cells compared to PT, and downstream
effector seems present in PTC but not in PT indicating rescue of downstream Notch
signaling.
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Chapter 4 Discussion
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CRISPR/Cas9 based gene editing in muscle disorders provides promising
technology in conjunction with patient-derived iPSCs for disease modeling and
development of treatment for rare diseases. Currently there is no cure for muscular
dystrophies and therapy consists of steroids, physical and surgical therapies for
increasing range of motion, and management of disease related symptoms that often
result in death (Mah, 2016). There are currently many therapies being developed ranging
from use of iPSCs for disease modeling, drug screening to evaluate affected pathways
and possible drug targets, and gene correction methods to look at global rescue of either
full or partial muscle function (Ortiz-Vitali, 2019).
In this study, we aimed to generate a CRISPR/Cas9n based gene targeting
construct to correct a homozygous recessive missense point mutation in a patient-derived
cell line with a novel form of muscular dystrophy named LGMD2Z. Unlike DMD where the
dystrophin gene is far too large, and mutations are far too variable, for a full gene targeting
strategy, the presence of a single point mutation allows for use of this technology to study
this novel LGMD. The Cas9 wild type nuclease system is a popular choice for engineering
eukaryotic cells carrying specific mutations to drive NHEJ and HDR, however we utilized
the Cas9 D10A mutant which contains a mutation in the catalytic RuvC domain which
drives the DSB. This mutation allows for the Cas9 to generate a single-strand break as
opposed to DSB, and targeting using a pair of Cas9n allows for carrying out gene editing
with higher sequence specificity to reduce chance of off-target mutagenesis (Ran, et al.,
2013). This involves two offset gRNA pairs to nick both strands of the locus to drive HDR,
leading to advantages such as ease of customization, less off target effects and more
specificity, higher editing efficiencies (Ran, et al., 2013). An alternative targeting method
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was also tested using a single-strand oligonucleotide with wild-type Cas9 to generate
DSB and correct the point mutation (Igoucheva, Alexeev, & Yoon, 2001). However after
multiple attempts, this method was not successful and therefore we moved forward with
the conventionally corrected PTC Clone 9 for differentiation. In the future, to generate
higher efficiency of gene targeting, we will have to adjust our current strategy for targeting
to find the optimal concentrations of targeting construct and sgRNA Cas9n constructs to
increase correction percentage.
Using the patient-derived iPSCs, we also aimed to evaluate any rescue of
phenotype in the corrected versus uncorrected and control cell lines. Currently, there is
no established and widely accepted protocol for differentiation of hESCs or iPSCs to
skeletal muscle. To give and idea of how many protocols currently exist (not counting this
developed after the publication date, or those missed by the authors) Chal et al. compiled
a list of many directed differentiation protocols in 2017 in chronological order from 19922017. At the time of publication, there were 81 total cited protocols. Differences between
protocols included the type of format used, such as embryoid body or adherent cells,
whether or not serum was used, the pathways involved, and if sorting was involved (Chal
& Pourquié, 2017). Fortunately, by using a novel double-reporter hESC line, our lab has
recently established a more efficient myogenic differentiation protocol for hPSCs (Wu et
al. 2018). Using this directed differentiation protocol we seek to recapitulate, in stage 1
(MDM-1), the development of mesodermal progenitor cells by activation of Wnt signaling
(von Maltzahn, Chang, Bentzinger, & Rudnicki, 2012) through inhibition of GSK-3 using
the small molecule CHIR 99021. This small molecule is used in conjunction with a TGFβ inhibitor SB431542 (Inman, et al., 2002) since TGF-β is shown to repress
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myogenesis by Smad3 (Liu, Black, & Derynck, 2001). From day 5 onward to sorting
at day 15, the cells undergo further specification towards myogenic precursor cells
in stage 2 (MDM-II) recapitulating primary myogenesis with activation of early
myogenic genes such as PAX3 and PAX7, and later MYF5, MYOD, and lastly MHC
when cells reach full commitment after expansion and terminal differentiation (D5D25). To enrich for myogenic progenitor cells, our lab has discovered a unique set
of cell surface markers (CD10 + CD24 -) by using PAX7 and MYF5 double-reporter cell
line that identifies a population of myogenic progenitor cells (Wu et al. 2018). Using
this set of surface markers, we saw clear difference in percentage of CD10 +
(myogenic) cells in the corrected cells compared to the uncorrected cells. Coinciding
with an increase in population of myogenic cells by D15, overall proliferation of
corrected versus uncorrected cells showed significant improvement and rescue as
demonstrated in Figure 19. This is further confirmed with a significantly lower
percentage of myogenic cells (MYOG +) cells during at terminal differentiation in
uncorrected cells (Figure 20). In the discovery of the family containing the
homozygous missense mutation in POGLUT1, Servián-Morilla et al. claim that lack of
Notch signaling leads to loss of the Pax7+ quiescence satellite cell pool which is
responsible for muscle regeneration and maintenance of the stem cells of the muscle.
This dysregulation is said to lead to seemingly accelerated differentiation which ultimately
depletes the satellite cell pool sometime in late adulthood (Servián-Morilla, et al., 2016).
Interestingly, we observed significantly less (p<0.001) MHC expression (i.e.myogenic
cells) in uncorrected cells versus corrected, which indicates defective expansion ability of
uncorrected myogenic cells probably due to dysregulated Notch signaling and faster cell
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cycle exit.. While this does not completely support the hypothesis that patient cells
experience accelerated differentiation, it is likely that during late stage 2 of differentiation
(following sorting for enrichment of myogenic progenitors), cells within the population may
be differentiating early and dying soon thereafter, due to the lack of the environment to
support terminally differentiated cells (MDM-II is meant for expansion of progenitor cells
and not terminal differentiation). It is also important to note that the cells used to make
the claim that accelerated differentiation is observed in patient-derived cells comes from
primary myoblasts. It is possible that due to the increased myogenic capacity of directly
harvested and committed myoblasts, which might be in their late differentiation stage,
while iPSC-derived cells more recapitulate developmental stages of myogenesis.
Following differentiation of iPSCs to skeletal myogenic progenitors, we evaluated
the gene expression profile of three separate differentiation experiments in all three cell
lines (CTL, PT, and PTC). To get a look at temporal gene expression, we evaluated
specific time points during the process to get an idea what myogenic and notch signaling
genes looked like at important events during our differentiation protocol. We began with
Day 0 to get a look at the state of the iPSCs prior to beginning differentiation. D5 cells
mark the beginning of committed muscle progenitor cells, and Day 15 is the point at which
we sort the cells and further enrich the myogenic population. In the results, we labeled
the terminal differentiation samples as T, which all represent the final day of differentiation
in which samples were fixed for immunostaining, harvested for RNA samples as well as
total protein for western blot. In all cell lines, POGLUT1 mRNA expression remained fairly
consistent across all samples, and seemed to reach its highest expression at about D15.
Notch 1 and 3 seem to have completely different results in uncorrected cells versus
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corrected. Notch 1, which is responsible for maintenance of the Pax7+ satellite cell pool
(with Notch2), and maintains cells in an undifferentiated quiescent state (Fujimaki et al.
2017) seems to be upregulated in corrected cells, whereas Notch 3, mostly found in
vascular smooth muscle cells (Wang, Baron, & Trump, 2008) is higher in uncorrected
cells. While higher expression of NOTCH1 would indicate some level of rescue in
corrected cells, and correlate with the rescued DLL1 (which plays a role in maintain
satellite cell pool during development (Sun et al. 2008), HEY1 and HES1 expression, it is
possible that Notch 3 expression is being activated by DLL4 being expressed myogenic
progenitor cells, or satellite cells, which is activating NOTCH3 and attempting to maintain
the progenitor cell pool (Low et al. 2017). Currently, Notch signaling roles (canonically
and non-canonically) are not well understood, and crosstalk plays a strong role in
maintenance of satellite cell quiescence and activation. In the myogenic genes evaluated
by qPCR, it appears that in the uncorrected cells, MYF5 and MYOD expression are higher
than corrected cells. This supports the hypothesis that patient-derived cells experience
accelerated differentiation, however interestingly MHC expression is higher in corrected
cells. As mentioned before, it is possible that from Day 15 cells have begun to terminally
differentiate spontaneously and die before reaching terminal differentiation. This is
evident by the difference in total DAPI+ cells in the field of uncorrected cells versus healthy
patient and corrected cells in Figures 20 and 21. Remarkably, overall levels of PAX7 in
corrected cells were higher at each time point taken. Given that PAX7 is a major regulator
of satellite cell quiescence and maintenance, it is likely that uncorrected cells are lacking
mRNA expression due to dysregulated Notch signaling. While there are promising results
in gene expression such as rescued Notch, and Notch effector and ligand, signaling, as
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well as major quiescence regulator Pax7, it is important to also consider possible clonal
variations -differentiation of iPSCs, as well as possible variations related to myogenic
differentiation protocol. In addition, current 2-dimensional culture techniques appear to be
lacking in replicating the true niche for formation of quiescent muscle stem cells, and it is
likely that 3-dimensional or engineered scaffolds be a better option for this purpose.
Lastly, in western blot analysis of uncorrected and corrected cells, N1ICD and
N2ICD as well as downstream effector HES1 protein levels were evaluated. There is
clearly higher level of protein N2ICD (and possibly N1ICD) in corrected cells versus
uncorrected. Given the role of Notch 2 in regulation of quiescence and regeneration, it
appears that protein expression is rescued after correction, and there is higher level of
Notch signaling taking place. This is also evident in the level of downstream effector Hes1,
which is also rescued in corrected cells versus uncorrected. Given that N2ICD and Hes1,
a major downstream effector of Notch signaling responsible for suppressing differentiation
(Lahmann, et al., 2019) are rescued, it is clear that corrected cells have overall rescued
Notch signaling, and supports our hypothesis that patient cells experienced reduced
proliferation and decreased Notch signaling. More work is needed to evaluate if
differentiation is truly accelerated or spontaneous. In the future, enzymatic and
glycosylation studies of POGLUT1 enzyme from corrected and uncorrected cells are
needed to evaluate the activity of POGLUT1 overall and towards glycosylation of EGF
repeats in potential targets. Importantly, it would be also valuable to evaluate in vivo mice
studies with patient corrected and uncorrected cells to determine the potential for
myofiber engraftment and donor-derived satellite cell replenishment potential of the cells.
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